Biologic therapies for the treatment of rheumatoid arthritis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Sung-Jae | - |
dc.date.accessioned | 2021-12-04T06:41:46Z | - |
dc.date.available | 2021-12-04T06:41:46Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2021-02 | - |
dc.identifier.issn | 1975-8456 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/129307 | - |
dc.description.abstract | Rheumatoid arthritis (RA) is a chronic autoimmune disease that primarily affects the synovial joints. If left untreated, persistent synovial inflammation can lead to cartilage and bone destruction, ultimately causing significant long-term disability and mortality. However, since the late 1990s, the combined use of methotrexate, a synthetic disease-modifying antirheumatic drug (DMARD), and a biological DMARD has revolutionized the treatment of RA. As of 2021, the Korea Food and Drug Administration has approved seven biological DMARDs for RA treatment: four tumor necrosis factor-alpha inhibitors (infliximab, etanercept, adalimumab, and golimumab) and three non-tumor necrosis factor biological products (abatacept, rituximab, and tocilizumab). Although the use of biological products has allowed significant advances in the treatment of RA, there are certain drawbacks, such as high cost, increased infection risk, and the necessity for parenteral route product administration. Therefore, discontinuation of biological DMARD use without a resulting disease flare is the next treatment goal and a desirable result from the standpoint of risk reduction and cost-effectiveness, especially for patients with clinical remission. It is still unclear which biological product is the best. Clinicians must, therefore, personalize the sequence and strategy of treatment by considering patient characteristics, disease activity, comorbidity, and economic condition | - |
dc.language | Korean | - |
dc.language.iso | ko | - |
dc.publisher | KOREAN MEDICAL ASSOC | - |
dc.subject | NECROSIS-FACTOR-ALPHA | - |
dc.subject | ANTI-TNF THERAPY | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | MONOCLONAL-ANTIBODY | - |
dc.subject | INADEQUATE RESPONSE | - |
dc.subject | PHASE-II | - |
dc.subject | CERTOLIZUMAB PEGOL | - |
dc.subject | SAFETY | - |
dc.subject | EFFICACY | - |
dc.subject | METHOTREXATE | - |
dc.title | Biologic therapies for the treatment of rheumatoid arthritis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Sung-Jae | - |
dc.identifier.doi | 10.5124/jkma.2021.64.2.95 | - |
dc.identifier.scopusid | 2-s2.0-85103627486 | - |
dc.identifier.wosid | 000621030400002 | - |
dc.identifier.bibliographicCitation | JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, v.64, no.2, pp.95 - 104 | - |
dc.relation.isPartOf | JOURNAL OF THE KOREAN MEDICAL ASSOCIATION | - |
dc.citation.title | JOURNAL OF THE KOREAN MEDICAL ASSOCIATION | - |
dc.citation.volume | 64 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 95 | - |
dc.citation.endPage | 104 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002684406 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | NECROSIS-FACTOR-ALPHA | - |
dc.subject.keywordPlus | ANTI-TNF THERAPY | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | MONOCLONAL-ANTIBODY | - |
dc.subject.keywordPlus | INADEQUATE RESPONSE | - |
dc.subject.keywordPlus | PHASE-II | - |
dc.subject.keywordPlus | CERTOLIZUMAB PEGOL | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | METHOTREXATE | - |
dc.subject.keywordAuthor | Rheumatoid arthritis | - |
dc.subject.keywordAuthor | Treatment | - |
dc.subject.keywordAuthor | Biological products | - |
dc.subject.keywordAuthor | Antirheumatic drugs | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.